Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Emory University
National Institutes of Health Clinical Center (CC)
University of Rochester
St. Anna Kinderkrebsforschung
The First Affiliated Hospital of Soochow University
Hebei Senlang Biotechnology Inc., Ltd.
Gilead Sciences
Yale University
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
The Royal Bournemouth Hospital
St. Antonius Hospital